Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Infections 1Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

liposomal amphotericin B 2Voriconazole 2Ribavirin 2Levofloxacin 2Fluconazole 2Ciprofloxacin 2Cefazolin 2telaprevir 1peginterferon alfa-2a 1lime 1human papillomavirus vaccine, L1 type 16, 18 1amphotericin B, deoxycholate drug combination 1Vancomycin 1Valacyclovir 1Trimethoprim, Sulfamethoxazole Drug Combination 1Trimethoprim 1Therapeutics 1Tazobactam 1Surgical Procedures, Operative 1Sulfamethoxazole 1Piperacillin, Tazobactam Drug Combination 1Piperacillin 1Palivizumab 1Olive Oil 1Ofloxacin 1Nystatin 1Moxifloxacin 1Itraconazole 1Diet 1Cefepime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Infections × telaprevir × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡